通策醫療(600763.SH):通策健康擬向合營企業提供不超2.9億元財務資助
格隆匯 10 月 20日丨通策醫療(600763.SH)公佈,公司全資子公司杭州通策健康管理服務有限公司(“通策健康”)擬向合營企業杭州捷木股權投資管理有限公司(“捷木投資”)提供不超過人民幣2.9億元的財務資助,其他股東按持股比例以同等條件零利率提供財務資助,期限自財務資助之日起至所建總部大樓取得單獨產權分立為上市公司直接持有為止。
公司持有捷木投資50%股權,捷木投資為公司的合營企業,故上述事項構成關聯交易。該事項不構成《上市公司重大資產重組管理辦法》規定的重大資產重組,尚需提交股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.